Role of sphingosine 1-phosphate receptors, sphingosine kinases and sphingosine in cancer and inflammation

Advances in Biological Regulation

Volumn 60, Issue , 2016, Pages 151-159

  Pyne, Nigel J ^a   McNaughton, Melissa ^a   Boomkamp, Stephanie ^a   MacRitchie, Neil ^a   Evangelisti, Cecilia ^b   Martelli, Alberto M ^b   Jiang, Hui Rong ^a   Ubhi, Satvir ^a   Pyne, Susan ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHOTRANSFERASE; SPHINGOSINE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE KINASE;

ANIMAL; ENZYMOLOGY; GENETICS; HUMAN; INFLAMMATION; METABOLISM; NEOPLASM;

ANIMALS; HUMANS; INFLAMMATION; NEOPLASMS; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); RECEPTORS, LYSOSPHINGOLIPID; SPHINGOSINE;

EID: 84958776846     PISSN: 22124926     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.jbior.2015.09.001     Document Type: Review

References (62)

1. Albinet V., Bats M.L., Huwiler A., Rochaix P., Chevreau C., Ségui B., Levade T., Andrieu-Abadie N. Dual role of sphingosine kinase-1 in promoting the differentiation of dermal fibroblasts and the dissemination of melanoma cells. Oncogene 2014, 33:3364-3373.
2. Allende M.L., Sasaki T., Kawai H., Olivera A., Mi Y., van Echten-Deckert G., Hajdu R., Rosenbach M., Keohane C.A., Mandala S., Spiegel S., Proia R.L. Mice deficient in sphingosine kinase 1 are rendered lymphopenic by FTY720. J. Biol. Chem. 2004, 279:52487-52492.
3. Baek D.J., MacRitchie N., Anthony N.G., Mackay S.P., Pyne S., Pyne N.J., Bittman R. Structure-activity relationships and molecular modeling of sphingosine kinase inhibitors. J. Med. Chem. 2013, 56:9310-9327.
4. Blaho V.A., Hla T. An update on the biology of sphingosine 1-phosphate receptors. J. Lipid Res. 2014, 55:1596-1608.
5. Boomkamp S.D., Byun H.S., Ubhi S., Jiang H.-R., Pyne S., Bittman R., Pyne N.J. Effect of ether glycerol lipids on interleukin-1β release and experimental autoimmune encephalomyelitis. Chem. Phys. Lipids 2015, (in press).
6. Brough D., Rothwell N.J. Caspase-1-dependent processing of prointerleukin-1 beta is cytosolic and precedes cell death. J. Cell Sci. 2007, 120:772-781.
7. Byun H.S., Pyne S., Macritchie N., Pyne N.J., Bittman R. Novel sphingosine-containing analogues selectively inhibit sphingosine kinase (SK) isozymes, induce SK1 proteasomal degradation and reduce DNA synthesis in human pulmonary arterial smooth muscle cells. MedChemComm 2013, 4:1394-1399.
8. Cingolani F., Casasampere M., Sanllehí P., Casas J., Bujons J., Fabrias G. Inhibition of dihydroceramide desaturase activity by the sphingosine kinase inhibitor SKI II. J. Lipid Res. 2014, 55:1711-1720.
9. Compeyrot-Lacassagne S., Tran T.A., Guillaume-Czitrom S., Marie I., Koné-Paut I. Brain multiple sclerosis-like lesions in a patient with Muckle-Wells syndrome. Rheumatology 2009, 48:1618-1619.
10. Cosconati S., Novellino E. The first sphingosine 1-phosphate lyase inhibitors against multiple sclerosis: a successful drug discovery tale. J. Med. Chem. 2014, 57:5072-5073.
11. Degagné E., Saba J.D. S1pping fire: sphingosine-1-phosphate signaling as an emerging target in inflammatory bowel disease and colitis-associated cancer. Clin. Exp. Gastroenterol. 2014, 7:205-214.
12. Dobrowsky R., Kamibayashi C., Mumby M.C., Hannun Y.A. Ceramide activates heterotrimeric protein phosphatase 2A. J. Biol. Chem. 1993, 268:15523-15530.
13. Dodé C., Le DÛ N., Cuisset L., Letourneur F., Berthelot J.M., Vaudour G., Meyrier A., Watts R.A., Scott D.G., Nicholls A., Granel B., Frances C., Garcier F., Edery P., Boulinguez S., Domergues J.P., Delpech M., Grateau G. New mutations of CIAS1 that are responsible for Muckle-Wells syndrome and familial cold urticaria: a novel mutation underlies both syndromes. Am. J. Hum. Genet. 2002, 70:1498-1506.
14. Evangelisti C., Evangelisti C., Teti G., Chiarini F., Falconi M., Melchionda F., Pession A., Bertaina A., Locatelli F., McCubrey J.A., Baek D.J., Bittman R., Pyne S., Pyne N.J., Martelli A.M. Assessment of the effect of sphingosine kinase inhibitors on apoptosis, unfolded protein response and autophagy of T-cell acute lymphoblastic leukemia cells; indications for novel therapeutics. Oncotarget 2014, 5:7886-7901.
15. French K.J., Zhuang Y., Maines L.W., Gao P., Wang W., Beljanski V., Upson J.J., Green C.L., Keller S.N., Smith C.D. Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2. J. Pharmacol. Exp. Ther. 2010, 333:129-139.
16. Gao P., Smith C.D. Ablation of sphingosine kinase-2 inhibits tumor cell proliferation and migration. Mol. Cancer Res. 2011, 9:1509-1519.
17. Garber J. Notch emerges as a new cancer drug target. Natl. Cancer Inst. 2007, 99:1284-1285.
18. Gris D., Ye Z., Iocca H.A., Wen H., Craven R.R., Gris P., Huang M., Schneider M., Miller S.D., Ting J.P. NLRP3 plays a critical role in the development of experimental autoimmune encephalomyelitis by mediating Th1 and Th17 responses. J. Immunol. 2010, 185:974-981.
19. Hait N.C., Allegood J., Maceyka M., Strub G.M., Harikumar K.B., Singh S.K., Luo C., Marmorstein R., Kordula T., Milstien S., Spiegel S. Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science 2009, 325:1254-1257.
20. Hla T., Brinkmann V. Sphingosine 1-phosphate (S1P): physiology and the effects of S1P receptor modulation. Neurology 2011, 76:S3-S8.
21. Hornung V., Latz E. Critical functions of priming and lysosomal damage for NLRP3 activation. Eur. J. Immunol. 2010, 40:620-623.
22. Inoue M., Williams K.L., Gunn M.D., Shinohara M.L. NLRP3 inflammasome induces chemotactic immune cell migration to the CNS in experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. (USA) 2012, 109:10480-10485.
23. Kumar A., Byun H.S., Bittman R., Saba J.D. The sphingolipid degradation product trans-2-hexadecenal induces cytoskeletal reorganization and apoptosis in a JNK-dependent manner. Cell. Signal 2011, 23:1144-1152.
24. LaMontagne K., Littlewood-Evans A., Schnell C., O'Reilly T., Wyder L., Sanchez T., Probst B., Butler J., Wood A., Liau G., Billy E., Theuer A., Hla T., Wood J. Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. Cancer Res. 2006, 66:221-231.
25. Liang J., Nagahashi M., Kim E.Y., Harikumar K.B., Yamada A., Huang W.C., Hait N.C., Allegood J.C., Price M.M., Avni D., Takabe K., Kordula T., Milstien S., Spiegel S. Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer. Cancer Cell. 2013, 23:107-120.
26. Lim K.G., Sun C., Bittman R., Pyne N.J., Pyne S. (R)-FTY720 methyl ether is a specific sphingosine kinase 2 inhibitor: effect on sphingosine kinase 2 expression in HEK 293 cells and actin rearrangement and survival of MCF-7 breast cancer cells. Cell. Signal. 2011, 23:1590-1595.
27. Lim K.G., Tonelli F., Li Z., Lu X., Bittman R., Pyne S., Pyne N.J. FTY720 analogues as sphingosine kinase 1 inhibitors: enzyme inhibition kinetics, allosterism, proteasomal degradation, and actin rearrangement in MCF-7 breast cancer cells. J. Biol. Chem. 2011, 286:18633-18640.
28. Lim K.G., Tonelli F., Berdyshev E., Gorshkova I., Leclercq T., Pitson S.M., Bittman R., Pyne S., Pyne N.J. Inhibition kinetics and regulation of sphingosine kinase 1 expression in prostate cancer cells: functional differences between sphingosine kinase 1a and 1b. Int. J. Biochem. Cell. Biol. 2012, 44:1457-1464.
29. Long J.S., Edwards J., Watson C., Tovey S., Mair K.M., Schiff R., Natarajan V., Pyne N.J., Pyne S. Sphingosine kinase 1 induces tolerance to human epidermal growth factor receptor 2 and prevents formation of a migratory phenotype in response to sphingosine 1-phosphate in estrogen receptor-positive breast cancer cells. Mol. Cell. Biol. 2010, 30:3827-3841.
30. Long J.S., Fujiwara Y., Edwards J., Tannahill C.L., Tigyi G., Pyne S., Pyne N.J. Sphingosine 1-phosphate receptor 4 uses HER2 (ERBB2) to regulate extracellular signal regulated kinase-1/2 in MDA-MB-453 breast cancer cells. J. Biol. Chem. 2010, 285:35957-35966.
31. Loveridge C., Tonelli F., Leclercq T., Lim K.G., Long J.S., Berdyshev E., Tate R.J., Natarajan V., Pitson S.M., Pyne N.J., Pyne S. The sphingosine kinase 1 inhibitor 2-(p-hydroxyanilino)-4-(p-chlorophenyl)thiazole induces proteasomal degradation of sphingosine kinase 1 in mammalian cells. J. Biol. Chem. 2010, 285:38841-38852.
32. Luheshi N.M., Giles J.A., Lopez-Castejon G., Brough D. Sphingosine regulates the NLRP3-inflammasome and IL-1β release from macrophages. Eur. J. Immunol. 2012, 42:716-725.
33. Nakahara K., Ohkuni A., Kitamura T., Abe K., Naganuma T., Ohno Y., Zoeller R.A., Kihara A. The Sjögren-Larsson syndrome gene encodes a hexadecenal dehydrogenase of the sphingosine 1-phosphate degradation pathway. Mol. Cell. 2012, 46:461-471.
34. Nagahashi M., Hait N.C., Maceyka M., Avni D., Takabe K., Milstien S., Spiegel S. Sphingosine-1-phosphate in chronic intestinal inflammation and cancer. Adv. Biol. Regul. 2014, 54:112-120.
35. Newton J., Lima S., Maceyka M., Spiegel S. Revisiting the sphingolipid rheostat: evolving concepts in cancer therapy. Exp. Cell Res. 2015, 333:195-200.
36. Nicolas M., Wolfer A., Raj K., Kummer J.A., Mill P., van Noort M., Hui C.C., Clevers H., Dotto G.P., Radtke F. Notch1 functions as a tumor suppressor in mouse skin. Nat. Genet. 2003, 33:416-421.
37. Ohotski J., Long J.S., Orange C., Elsberger B., Mallon E., Doughty J., Pyne S., Pyne N.J., Edwards J. Expression of sphingosine 1-phosphate receptor 4 and sphingosine kinase 1 is associated with outcome in oestrogen receptor-negative breast cancer. Br. J. Cancer 2012, 106:1453-1459.
38. Ohotski J., Edwards J., Elsberger B., Watson C., Orange C., Mallon E., Pyne S., Pyne N.J. Identification of novel functional and spatial associations between sphingosine kinase 1, sphingosine 1-phosphate receptors and other signalling proteins that affect prognostic outcome in estrogen receptor-positive breast cancer. Int. J. Cancer 2013, 132:605-616.
39. Ohotski J., Rosen H., Bittman R., Pyne S., Pyne N.J. Sphingosine kinase 2 prevents the nuclear translocation of sphingosine 1-phosphate receptor-2 and tyrosine 416 phosphorylated c-Src and increases estrogen receptor negative MDA-MB-231 breast cancer cell growth: the role of sphingosine 1- phosphate receptor-4. Cell. Signal 2014, 26:1040-1047.
40. Ponnusamy S., Selvam S.P., Mehrotra S., Kawamori T., Snider A.J., Obeid L.M., Shao Y., Sabbadini R., Ogretmen B. Communication between host organism and cancer cells is transduced by systemic sphingosine kinase 1/sphingosine 1-phosphate signalling to regulate tumour metastasis. EMBO. Mol. Med. 2012, 4:761-775.
41. Pyne S., Lee S.C., Long J., Pyne N.J. Role of sphingosine kinases and lipid phosphate phosphatases in regulating spatial sphingosine 1-phosphate signalling in health and disease. Cell. Signal 2009, 21:14-21.
42. Pyne S., Edwards J., Ohotski J., Pyne N.J. Sphingosine 1-phosphate receptors and sphingosine kinase 1: novel biomarkers for clinical prognosis in breast, prostate, and hematological cancers. Front. Oncol. 2012, 2:168.
43. Pyne N.J., Ohotski J., Bittman R., Pyne S. The role of sphingosine 1-phosphate in inflammation and cancer. Adv. Biol. Regul. 2014, 54:121-129.
44. Pyne N.J., Pyne S. Sphingosine 1-phosphate and cancer. Nat. Rev. Cancer 2010, 10:489-503.
45. Pyne N.J., Pyne S. Sphingosine 1-phosphate is a missing link between chronic inflammation and colon cancer. Cancer Cell. 2013, 23:5-7.
46. Pyne N.J., Pyne S. Sphingosine kinase 1 enables communication between melanoma cells and fibroblasts that provides a new link to metastasis. Oncogene 2014, 33:3361-3363.
47. Schnute M.E., McReynolds M.D., Kasten T., Yates M., Jerome G., Rains J.W., Hall T., Chrencik J., Kraus M., Cronin C.N., Saabye M., Highkin M.K., Broadus R., Ogawa S., Cukyne K., Zawadzke L.E., Peterkin V., Iyanar K., Scholten J.A., Wendling J., Fujiwara H., Nemirovskiy O., Wittwer A.J., Nagiec M.M. Modulation of cellular S1P levels with a novel, potent and specific inhibitor of sphingosine kinase-1. Biochem. J. 2012, 444:79-88.
48. Shepherd C., Banerjee L., Cheung C.W., Mansour M.R., Jenkinson S., Gale R.E., Khwaja A. PI3K/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response. Leukemia 2013, 27:650-660.
49. Siow D., Sunkara M., Morris A., Wattenberg B. Regulation of de novo sphingolipid biosynthesis by the ORMDL proteins and sphingosine kinase-1. Adv. Biol. Regul. 2015, 57:42-54.
50. Stiban J., Tidhar R., Futerman A.H. Ceramide synthases: roles in cell physiology and signaling. Adv. Exp. Med. Biol. 2010, 688:60-71.
51. Sutton C., Brereton C., Keogh B., Mills K.H., Lavelle E.C. A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J. Exp. Med. 2006, 203:1685-1691.
52. Taha T.A., Kitatani K., El-Alwani M., Bielawski J., Hannun Y.A., Obeid L.M. Loss of sphingosine kinase-1 activates the intrinsic pathway of programmed cell death: modulation of sphingolipid levels and the induction of apoptosis. FASEB J. 2006, 20:482-484.
53. Tonelli F., Lim K.G., Loveridge C., Long J., Pitson S.M., Tigyi G., Bittman R., Pyne S., Pyne N.J. FTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promote its proteasomal degradation in human pulmonary artery smooth muscle breast cancer and androgen-independent prostate cancer cells. Cell. Signal 2010, 22:1536-1542.
54. Vadas M., Xia P., McCaughan G., Gamble J. The role of sphingosine kinase 1 in cancer: oncogene or non-oncogene addiction?. Biochim. Biophys. Acta 2008, 1781:442-447.
55. Venkata J.K., An N., Stuart R., Costa L.J., Cai H., Coker W., Song J.H., Gibbs K., Matson T., Garrett-Mayer E., Wan Z., Ogretmen B., Smith C., Kang Y. Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma. Blood 2014, 124:1915-1925.
56. Wallington-Beddoe C.T., Powell J.A., Tong D., Pitson S.M., Bradstock K.F., Bendall L.J. Sphingosine kinase 2 promotes acute lymphoblastic leukemia by enhancing MYC expression. Cancer Res. 2014, 74:2803-2815.
57. Wang J., Knapp S., Pyne N.J., Pyne S., Elkins J.M. Crystal Structure of sphingosine kinase 1 with PF-543. ACS Med. Chem. Lett. 2014, 5:1329-1333.
58. Watson C., Long J.S., Orange C., Tannahill C.L., Mallon E., McGlynn L.M., Pyne S., Pyne N.J., Edwards J. High expression of sphingosine 1-phosphate receptors, S1P1 and S1P3, sphingosine kinase 1, and extracellular signal-regulated kinase-1/2 is associated with development of tamoxifen resistance in estrogen receptor-positive breast cancer patients. Am. J. Pathol. 2010, 177:2205-2215.
59. Watson D.G., Tonelli F., Alossaimi M., Williamson L., Chan E., Gorshkova I., Berdyshev E., Bittman R., Pyne N.J., Pyne S. The roles of sphingosine kinases 1 and 2 in regulating the Warburg effect in prostate cancer cells. Cell. Signal 2013, 25:1011-1017.
60. Xia P., Gamble J.R., Wang L., Pitson S.M., Moretti P.A., Wattenberg B.W., D'Andrea R.J., Vadas M.A. An oncogenic role of sphingosine kinase. Curr. Biol. 2000, 10:1527-1530.
61. Zhou H., Summers S.A., Birnbaum M.J., Pittman R.N. Inhibition of Akt kinase by cell-permeable ceramide and its implications for ceramide-induced apoptosis. J. Biol. Chem. 1998, 273:16568-16575.
62. Zundel W., Giaccia A. Inhibition of the anti-apoptotic PI(3)K/Akt/Bad pathway by stress. Genes Dev. 1998, 12:1941-1946.